Onkos Surgical announced a new FDA 510(k) clearance on November 6, 2026, for its NanoCept Antibacterial Technology, expanding its application to a broader range of titanium components in the ELEOS Limb Salvage System.
What it means for surgery
According to Dr. Johannes Plate, Director of Adult Reconstruction Research at University of Pittsburgh Medical Center, complex joint replacement and limb salvage procedures present unique challenges for patients at increased risk for periprosthetic joint infection. Having antibacterial protection on a broad range of implants helps surgeons minimize the risk of bacterial contamination in this vulnerable patient population.
Patrick Treacy, Founder and CEO of Onkos Surgical, stated that the regulatory milestone reinforces the company's commitment to deliver a comprehensive antibacterial-coated implant system that evolves alongside surgeon and patient needs.
Expansion details
The new clearance extends NanoCept to additional titanium components of the ELEOS system, including proximal femurs, tibial baseplates and augments, and cemented bowed segmental stems. It also permits broader NanoCept coverage on previously cleared titanium components.
This advancement builds on an FDA clearance earlier in the year for the application of NanoCept to titanium implants. It marks the fourth 510(k) clearance for NanoCept since its De Novo authorization in April 2024.
Preclinical testing and limitations
NanoCept is a proprietary antibacterial implant coating designed to reduce bacterial contamination of implant surfaces in the operating room prior to implantation. Extensive preclinical testing has demonstrated up to a 99.999 percent reduction in bacteria commonly found in the operating room.
Onkos noted that NanoCept is not intended to treat existing infections. Furthermore, the clinical impact associated with NanoCept, including the prevention or reduction of infection risk in patients, has not been evaluated in human clinical trials.
Key facts and where they come from
- Onkos Surgical announced a new FDA 510(k) clearance for NanoCept Antibacterial Technology.
Onkos Surgical, Inc. today announced a new FDA 510(k) clearance for its NanoCept® Antibacterial Technology
- The clearance marks the fourth 510(k) clearance for NanoCept since April 2024.
It marks the fourth 510(k) clearance for NanoCept since the technology's groundbreaking De Novo authorization in April 2024
- Preclinical testing demonstrated up to a 99.999 percent reduction in bacteria commonly found in the operating room.
Extensive preclinical testing has demonstrated up to a 99.999% reduction in bacteria commonly found in the operating room.
The open question: How will post-market clinical results compare to the in-vitro preclinical test results for NanoCept-coated components?
Tell us what you think · Discuss it in the Startups & Funding room
